Explore KEYTRUDA® dosing in:
-
Recommended dosage for cervical cancer (persistent, recurrent or metastatic)
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeksuntil disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
Administer KEYTRUDA® prior to chemotherapy with or without bevacizumab when given on the same day. Refer to the Product Monographs for the chemotherapy or other agents administered in combination with KEYTRUDA® for further information, as appropriate.
-
Recommended dosage for MSI-H colorectal cancer – Previously untreated for metastatic disease and previously treated for unresectable or metastatic disease
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity, or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
MSI-H=microsatellite instability-high.
-
Recommended dosage for endometrial carcinoma (not MSI-H or dMMR)
For adult patients with endometrial carcinoma that is not MSI-H or dMMR, the recommended dosing is:
- KEYTRUDA® – administered as an intravenous infusion over 30 minutes
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until unacceptable toxicity, disease progression, or for up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in combination with;
- Lenvatinib – 20 mg orally once daily until unacceptable toxicity or disease progression.
Refer to the Lenvatinib Product Monograph for recommended Lenvatinib dosing information.
MSI-H=microsatellite instability-high; dMMR=mismatch repair deficient
- KEYTRUDA® – administered as an intravenous infusion over 30 minutes
-
Recommended dosage for MSI-H colorectal or endometrial cancer patients – previously treated for unresectable or metastatic disease
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression or unacceptable toxicity, or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
MSI-H=microsatellite instability-high.
-
Recommended dosage for esophageal cancer, in combination with platinum and fluoropyrimidine-based chemotherapy
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity or up to 24 months.
Administer KEYTRUDA® prior to chemotherapy when given on the same day.
-
Recommended dosage for head and neck squamous cell carcinoma – previously untreated as monotherapy or in combination with chemotherapy
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
When administering KEYTRUDA® in combination with chemotherapy, administer KEYTRUDA® prior to chemotherapy when given on the same day. Refer to the Product Monographs for the chemotherapy agents administered in combination with KEYTRUDA® for recommended dosing information, as appropriate.
-
Recommended dosage for Hodgkin lymphoma
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA®:
- in adults is either
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
- in pediatric patients is 2 mg/kg (up to a maximum of 200 mg) every 3 weeks
until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression.
- in adults is either
-
Recommended dosage for PMBCL
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either
- 200 mg every 3 weeks; OR
- 400 mg every 6 weeks
The recommended dose of KEYTRUDA® in pediatric patients is 2 mg/kg (up to a maximum of 200 mg) every 3 weeks.
-
Recommended dosage for unresectable or metastatic melanoma
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression or unacceptable toxicity. It is expected that patients will continue to experience a similar safety and efficacy profile on this regimen as they have had on the previous one of 2 mg/kg every 3 weeks.
Recommended dosage for adjuvant treatment of melanoma
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
for up to one year or until disease recurrence or unacceptable toxicity.
The recommended dose of KEYTRUDA® in pediatric patients 12 years and older with stage IIB and IIC melanoma is 2 mg/kg (up to a maximum of 200 mg) every 3 weeks until disease progression or unacceptable toxicity, or up to 12 months.
-
Recommended dosage for previously untreated NSCLC as monotherapy or in combination with chemotherapy
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
When administering KEYTRUDA® as part of a combination with pemetrexed and platinum chemotherapy, KEYTRUDA® should be administered first. See also the Product Monographs for pemetrexed and the selected platinum chemotherapy.
Recommended dosage for NSCLC – previously treated
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression or unacceptable toxicity. It is expected that patients will continue to experience a similar safety and efficacy profile on this regimen as they have had on the previous one of 2 mg/kg every 3 weeks.
Recommended Dosage for Adjuvant Treatment of NSCLC
KEYTRUDA® is administered as an intravenous infusion over 30 minutes
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks or
- 400 mg every 6 weeks
for up to one year or until disease recurrence or unacceptable toxicity.
-
Recommended dosage for advanced or metastatic RCC with no prior systemic therapy for metastatic RCC in combination with axitinib
For adult patients with RCC, the recommended dosing is:
- KEYTRUDA® – administered as an intravenous infusion over 30 minutes
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression or unacceptable toxicity, or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in combination with;
- Axitinib – 5 mg axitinib orally twice daily until unacceptable toxicity or disease progression. As in KEYNOTE-426, when axitinib is used in combination with KEYTRUDA®, dose escalation may be considered for patients who tolerated the initial 5 mg axitinib dose at intervals of six weeks or longer (i.e., at least 2 treatment cycles). Refer to the axitinib Product Monograph for recommended axitinib dose information.
Recommended dosage for advanced or metastatic RCC with no prior systemic therapy for metastatic RCC in combination with lenvatinib
For adult patients with RCC, the recommended dosing is:
- KEYTRUDA® – administered as an intravenous infusion over 30 minutes
- 200 mg every 3 weeks; or
- 400 mg every 6 weeksuntil disease progression or unacceptable toxicity, or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in combination with;
Recommended dosage for adjuvant treatment of RCC
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeksuntil disease progression or unacceptable toxicity, or up to 1 year (12 months) or 17 doses for 200 mg or 9 doses for 400 mg, whichever is longer, in patients without disease recurrence.
- KEYTRUDA® – administered as an intravenous infusion over 30 minutes
-
Recommended dosage for locally recurrent unresectable or metastatic TNBC in combination with chemotherapy
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
When administering KEYTRUDA® in combination with chemotherapy, administer KEYTRUDA® prior to chemotherapy when given on the same day. Refer to the Product Monographs for the chemotherapy agents administered in combination with KEYTRUDA® for recommended dosing information, as appropriate.
Recommended Dosage for TNBC – high-risk early-stage in combination with chemotherapy asneoadjuvant treatment, then as monotherapy as adjuvant treatment after surgery
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
For the neoadjuvant and adjuvant treatment of early-stage TNBC, patients should be treated with neoadjuvant KEYTRUDA® in combination with chemotherapy for 8 doses of 200 mg every 3 weeks or 4 doses of 400 mg every 6 weeks or until disease progression that precludes definitive surgery or nacceptable toxicity, followed by adjuvant treatment with KEYTRUDA® as monotherapy for 9 doses of 200 mg every 3 weeks or 5 doses of 400 mg every 6 weeks or until disease recurrence or unacceptable toxicity. Patients who experience disease progression that precludes definitive surgery or unacceptable toxicity related to KEYTRUDA® as neoadjuvant treatment in combination with chemotherapy should not receive KEYTRUDA® monotherapy as adjuvant treatment.
When administering KEYTRUDA® in combination with chemotherapy, administer KEYTRUDA® prior to chemotherapy when given on the same day. Consult the of the study for the chemotherapy regimen used (containing carboplatin and paclitaxel, followed by doxorubicin or epirubicin and cyclophosphamide). Refer to the Product Monographs for the chemotherapy agents administered in combination with KEYTRUDA® for recommended dosing information, as appropriate.
-
Recommended dosage for urothelial carcinoma – previously treated
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks until disease progression or unacceptable toxicity, or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
Recommended dosage for urothelial carcinoma – not eligible for platinum-containing chemotherapy.
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeksuntil disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
Recommended dosage for BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC)
KEYTRUDA® is administered as an intravenous infusion over 30 minutes.
The recommended dose of KEYTRUDA® in adults is either:
- 200 mg every 3 weeks; or
- 400 mg every 6 weeks
until disease progression, unacceptable toxicity or up to 24 months or 35 doses for 200 mg or 18 doses for 400 mg, whichever is longer, in patients without disease progression.
Important information relevant to all KEYTRUDA® indications
Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. Clinically stable patients with initial evidence of disease progression may remain on treatment until disease progression is confirmed.